Clinical and electrophysiologic effects of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with angina pectoris☆

https://doi.org/10.1016/0002-9149(92)90996-CGet rights and content

Abstract

Dofetilide (UK-68,798) is a new class III antiarrhythmic agent. In animal experiments it selectively prolongs the refractory periods parallel to the action potential duration without any influence on upstroke velocity or conduction parameters. The present double-blind, placebo-controlled study was designed to show the effect of dofetilide on basic electrophysiologic parameters in patients with coronary artery disease. Eighteen patients (aged 31 to 64 years) with symptoms of stable angina pectoris admitted for routine coronary angiography were recruited. They were randomly allocated to receive either placebo or 1 of 2 dose levels of dofetilide intravenously with 6 patients in each group. Paired electrophysiologic variables were compared before and after administration of dofetilide.

Both active dose levels produced significant prolongations (p < 0.05) of 10 to 23% in atrial effective refractory period, 6 to 16% in ventricular effective refractory period and 11 to 15% in ventricular functional refractory period. Atrial functional refractory period was prolonged by 14 to 22% at the high-dose level (p < 0.05). No effect was observed on conduction parameters (PA, AH, HV, PR or QRS intervals), sinus cycle length or sinus node recovery. The selective prolongation of the refractory periods in both atrium and ventricle, combined with a lack of effect on cardiac conduction parameters, indicates that this drug could be useful in the treatment of both atrial and ventricular reentrant tachyarrhythmias and fibrillation.

References (23)

  • DK Walker et al.

    Measurements of the class III antidysrhythmic drug UK-68,798 in plasma by radioimmunoassay

    J Pharm Biomed Anal

    (1991)
  • JL Willems et al.

    A reference data base for multilead electrocardiographic computer measurement programs

    J Am Coll Cardiol

    (1987)
  • R Neri et al.

    Ventricular arrhythmias in dilated cardiomyopathy: efficacy of amiodarone

    Am Heart J

    (1987)
  • Cardiac arrhythmia suppression trial (CAST) investigators

    Preliminary report, effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction

    N Engl J Med

    (1989)
  • DS Echt et al.

    Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

    N Engl J Med

    (1991)
  • BN Singh

    Amiodarone: electropharmacologic properties

  • SM Cobbe

    Sotalol

  • SD Gokhale et al.

    Mechanisms of the initial adrenergic effects of bretylium and guanethidine

    Br J Pharmacol

    (1963)
  • M Gwilt et al.

    UK-68,798: a novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells

    J Pharmacol Exp Ther

    (1991)
  • G Zuanetti et al.

    Antiarrhythmic efficacy of a new class III agent, UK-68,798 during chronic myocardial infarction: evaluation using three dimensional mapping

    J Pharmacol Exp Ther

    (1991)
  • PM Tande et al.

    Rate-dependent class III antiarrhythmic action, negative chronotropy, and positive inotropy of a novel Ik blocking drug, UK-68,798: potent in guinea pig but no effect in rat myocardium

    J Cardiocasc Pharmacol

    (1990)

    • Cited by (66)

    • Comparative Efficacy of Dofetilide Versus Amiodarone in Patients With Atrial Fibrillation

      2021, JACC: Clinical Electrophysiology

    • Dofetilide: Electrophysiologic Effect, Efficacy, and Safety in Patients with Cardiac Arrhythmias

      2016, Cardiac Electrophysiology Clinics
      Citation Excerpt :

      VT of TdP form was developed in 2 patients (3%) and IV infusion was discontinued before the end of the study. A few other trials on IV dofetilide have been carried out and provided similar results.50,51 Dofetilide has no effect on PR interval and QRS duration.

    • Dofetilide induced torsade de pointes: Mechanism, risk factors and management strategies

      2014, Indian Heart Journal
      Citation Excerpt :

      This results in prolongation of action potential duration and effective refractory period. At the recommended doses, it causes selective prolongation of the QT interval on the surface electrocardiogram (EKG) without any effect on PR, QRS, AH or HV intervals.2 This happens due to the lack of effect on slow component of the delayed rectifier potassium current (Iks), the inward current (IK1), any sodium channel (INa), calcium channel (ICa) or beta-receptor.3

    • Interpretation of Clinical Trials: How Mortality Trials Relate to the Therapy of Atrial Fibrillation

      2005, Electrophysiological Disorders of the Heart

    • Dofetilide: Is the treatment worse than the disease?

      2001, Journal of the American College of Cardiology
      Citation Excerpt :

      All of the active drug groups were statistically different from placebo. Dofetilide prolongs the action potential duration and QT interval in a concentration-dependent fashion (6,8). Reports of the early incidence of torsade de pointes by QT-prolonging antiarrhythmic agents range from 0.5% to 8% (15–19).

    • Effect of dofetilide on the pharmacokinetics of digoxin

      2001, American Journal of Cardiology
    View all citing articles on Scopus
    ☆

    This study was supported by a grant from Pfizer Central Research.

    View full text
    Copyright © 1992 Published by Elsevier Inc.